grunenthal and YOU GO have reached an exclusive agreement for the marketing, distribution and promotion of Tetridar in the Spanish market. This agreement is expected to be extended to fend of 2027, with the possibility of extension.
João SimõesCEO of Grünenthal Pharma, values this type of partnerships for the benefit of patientsnoting that “Thanks to this collaboration between companies, more people affected by osteoporosis and with high risk of fracture will improve their quality of life. This disease and its consequences greatly affect those who suffer from it, since it causes pain and disability. This drug joins our portfolio, thus incorporating a cutting edge drug that will improve the lives of these people”.
Tetridar is a medication in pre-filled pen format whose active ingredient is teriparatide and is indicated for the treatment of osteoporosis.
For his part, Carlos Teixeirageneral director of TEVA, indicates that “for TEVA it is important weave alliances that help our drugs reach millions of people. In this case, together with a company like Grünenthal, we want those people who suffer from osteoporosis to have a good access to our product and can benefit from it”.
grunenthal will commercialize Tetridar in the Spanish market, a medication in pre-filled pen formatwhose active ingredient is teriparatide and is indicated on the osteoporosis treatment thus avoiding the high risk of fractures. It’s about a chemical synthesis drugbioequivalent to the reference product (Forsteo), whose active substance is teriparatide. It is indicated in the treatment of osteoporosis in postmenopausal women and in men with increased risk of fracture, as well as in osteoporosis associated with maintained systemic therapy with glucocorticoids. In Spain, 2.4 million people over 50 years of age suffered from osteoporosis in 20103.
The teriparatide is a solution for injection in a pre-filled pen for subcutaneous administration. has shown that significantly reduces the occurrence of fracturevertebral and non-vertebral s in patients with osteoporosis. Also, the use of teriparatide can significantly relieve lower back painimprove the patient’s quality of life and increase mobility in patients with postmenopausal osteoporosis.
It is estimated that in the world there is a new vertebral fracture every 22 seconds and the osteoporotic type of fracture is the most common. In addition, its incidence is increasing mainly due to a longer life expectancy. Despite many spinal fractures cause pain and disability, they are often ignored or treated as simple back pain. However, vertebral fractures lead to a severe deformity spine, back pain, loss of height, immobility, depression, increased number of days off, impaired lung function, and premature death.
CuidarT Patient Support Program
Besides, launches the CuidarT Patient Support Program, in order to train and empower them in the treatment with this medicine. This program consists of a Tetridar patient training about the correct administration of the drug, the use of the proper injection technique and correct use of the pen. Likewise, Grünenthal makes available to these patients a dedicated free telephone number attended by adequately trained and experienced nursing professionals.
All this in order to achieve a adequate therapeutic compliance for optimal adherence and greater effectiveness of treatment. This program will also facilitate correct pharmacovigilance with monitoring of the prevention, management and reporting of adverse events.